LeadershipPsychiatry
June 26, 2018

Saladax Signs Licensing Agreement with Janssen for Antipsychotic Drug Testing Patents

BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc., a diagnostics company providing kits to measure drug blood levels…
Read More
LeadershipPsychiatry
March 21, 2018

Saladax Receives Approval to Sell a New Line of Psychiatry Tests on the European Market

Saladax is Advancing Personalized Medicine by Providing Doctors with Tests for Drug Levels to Better…
Read More
OncologyPaclitaxel
October 14, 2017

Saladax is Awarded “Best Poster Presentation” for Study on Individualized Dosing of Paclitaxel

Saladax Biomedical, Inc., recently presented a study on the value of adjusting paclitaxel doses.  The…
Read More
Neurology
January 18, 2017

Saladax Licenses Alzheimer’s Diagnostic Tests to Siemens Healthineers

Tests can lead to early identification of Alzheimer’s Disease Bethlehem, PA--(BUSINESS WIRE)--January 18, 2017-- Saladax…
Read More
Leadership
October 28, 2016

Salvatore J. Salamone, Ph.D., Founder and CEO of Saladax Biomedical, Inc. Inducted into the New Jersey Inventors Hall of Fame

Saladax Biomedical, Inc., the leader in developing oncology diagnostics that increase the impact of personalized…
Read More
OncologyPaclitaxel
October 19, 2016

Study Shows That Therapeutic Drug Monitoring Can Reduce Paclitaxel-Associated Neuropathy

Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic tests, today announced…
Read More
OncologyPaclitaxel
June 9, 2015

Saladax Biomedical, Inc. Announces Presentation of CEPAC-TDM Study of Paclitaxel in Non-Small Cell Lung Cancer at 2015 ASCO Meeting

Large Study Confirms the Benefit to Patients of Advanced Dosing Method for Saladax Biomedical, Inc.…
Read More
5-FU
June 8, 2015

Saladax Biomedical, Inc. Announces the Presentation of the CESAR Study Results for Pharmacokinetically-Guided Dosing of 5-Fluorouracil in Colorectal Cancer at 2015 ASCO Meeting

Advantages of a Practical Approach to Personalized Dosing of 5-FU Demonstrated Saladax Biomedical, Inc. recently…
Read More
ImatinibOncology
December 1, 2014

Saladax Biomedical Announces U.S. Launch of MyImatinib™ Chemotherapy Exposure Optimization Test

Commercial Launch of MyImatinib™ Test Expands MyCare™ portfolio of Chemotherapy Exposure Optimization tests available from…
Read More
Leadership
July 23, 2014

Personalized Chemotherapy Tests Cleared for Use in China

Exposure Optimization Tests Fosun Diagnostics, a division of Fosun Pharmaceuticals, and Saladax Biomedical, Inc. today…
Read More